Key result
WWP1 deficiency alleviated simulated microgravity-induced cardiac atrophy and function decline in mice by inhibiting the DVL2/CaMKII/HDAC4 pathway.
Why the study?
Microgravity can cause cardiac remodeling and function decline, but the underlying mechanism and the role of WWP1 remain unknown.
Does WWP1 deficiency prevent simulated microgravity-induced cardiac remodeling and function decline in preclinical models?
Does WWP1 deficiency prevent simulated microgravity-induced cardiac remodeling and function decline in preclinical models?
p-value: p=0.0351
WWP1 knockout protects against simulated microgravity-induced cardiac atrophy and dysfunction by inhibiting the DVL2/CaMKII/HDAC4 pathway, suggesting WWP1 as a potential therapeutic target for spaceflight-induced cardiac remodeling.
WWP1 targeting may protect against microgravity cardiac effects; leaves open translation beyond animal models.
Cardiac muscle is extremely sensitive to changes in loading conditions; the microgravity during space flight can cause cardiac remodeling and function decline. At present, the mechanism of microgravity-induced cardiac remodeling remains to be revealed. WW domain-containing E3 ubiquitin protein ligase 1 (WWP1) is an important activator of pressure overload-induced cardiac remodeling by stabilizing disheveled segment polarity proteins 2 (DVL2) and activating the calcium-calmodulin-dependent protein kinase II (CaMKII)/histone deacetylase 4 (HDAC4)/myocyte-specific enhancer factor 2C (MEF2C) axis. However, the role of WWP1 in cardiac remodeling induced by microgravity is unknown. The purpose of this study was to determine whether WWP1 was also involved in the regulation of cardiac remodeling caused by microgravity. Firstly, we detected the expression of WWP1 and DVL2 in the heart from mice and monkeys after simulated microgravity using western blotting and immunohistochemistry. Secondly, WWP1 knockout (KO) and wild-type (WT) mice were subjected to tail suspension (TS) to simulate microgravity effect. We assessed the cardiac remodeling in morphology and function through a histological analysis and echocardiography. Finally, we detected the phosphorylation levels of CaMKII and HDAC4 in the hearts from WT and WWP1 KO mice after TS. The results revealed the increased expression of WWP1 and DVL2 in the hearts both from mice and monkeys after simulated microgravity. WWP1 deficiency alleviated simulated microgravity-induced cardiac atrophy and function decline. The histological analysis demonstrated WWP1 KO inhibited the decreases in the size of individual cardiomyocytes of mice after tail suspension. WWP1 KO can inhibit the activation of the DVL2/CaMKII/HDAC4 pathway in the hearts of mice induced by simulated microgravity. These results demonstrated WWP1 as a potential therapeutic target for cardiac remodeling and function decline induced by simulated microgravity.
No takes yet. Share an insight, caveat, or question.
Zhong et al. (2021) studied Simulated microgravity-induced cardiac remodeling. WWP1 knockout vs. Wild-type mice was evaluated on Left ventricular ejection fraction (EF) (p=0.0351). WWP1 deficiency alleviated simulated microgravity-induced cardiac atrophy and function decline in mice by inhibiting the DVL2/CaMKII/HDAC4 pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: